Continuous Comprehensive Nursing for Post-CABG Recovery

Evaluating the Efficacy of a Continuous Comprehensive Nursing System on Postoperative Hemoglobin Levels and Quality of Life in Patients Undergoing Coronary Artery Bypass Surgery

This study evaluates the effectiveness of a continuous comprehensive nursing (CCN) system compared to routine care for patients after coronary artery bypass graft (CABG) surgery. The primary goal is to determine if the CCN system improves postoperative hemoglobin levels. The study also investigates the effects on quality of life, mental health (anxiety and depression), red blood cell indices, immune markers, and patient satisfaction.

Coronary artery bypass surgery (CABG) is a major procedure, and the postoperative recovery process is complex, often impacting patients' hemoglobin levels and quality of life. Standard nursing care is often limited to the inpatient period. A continuous comprehensive nursing (CCN) system is a holistic, patient-centered model that extends care beyond hospital discharge. This model includes preoperative education, continuous monitoring, personalized care plans, psychological support, rehabilitation guidance, and structured follow-up. While the benefits of comprehensive nursing are recognized, its specific impact on hemoglobin recovery and quality of life after CABG has not been extensively studied. This randomized controlled trial was designed to compare the outcomes of patients receiving a CCN plan with those receiving routine postoperative care to provide evidence for optimizing post-CABG nursing strategies.

Inclusion Criteria:

• Age between 18 and 70 years.
• Confirmed diagnosis of coronary heart disease and evidence of coronary artery illness requiring CABG.
• Ability to understand the purpose and procedures of the study.
• Willingness to sign the informed consent form.

Exclusion Criteria:

• Presence of serious complications such as unstable myocardial ischemia or significant arrhythmia.
• Severe lung diseases (e.g., chronic obstructive pulmonary disease GOLD stage III/IV).
• Severe kidney diseases (e.g., chronic kidney disease Stage 4/5).
• Significantly impaired left ventricular ejection fraction (EF < 30%).
• Concurrent participation in other clinical trials or receiving other interventions.
• Presence of severe mental illnesses or cognitive impairments.